THR-317, a humanized antibody against placental growth factor, combined with ranibizumab showed no improvement in mean best corrected visual acuity compared with ranibizumab monotherapy in a phase 2a study, Oxurion announced in a press release.
The randomized, single-masked, active-controlled, multicenter study included 70 patients with diabetic macular edema who were treated with a combination of THR-317 and ranibizumab or ranibizumab and sham.
In the overall population of those treated with combination therapy, a mean increase in BCVA of 8.71 letters was observed after three monthly
Uncategorized